530-75-6

Basic information

• Product Name: ACETYLSALICYLSALICYLIC ACID
• Synonyms: o-(o-Acetoxybenzoyloxy)benzoic acid;2-(Ace;Aspirin EP IMpurity D;Aspirin IMpurity D;2-((2-Acetoxybenzoyl)oxy)benzoic acid,95+%;DIPLOSALSALATE;(Acetysalicylsalicyclic acid);Acetylsalicylic Acid IMpurity D (Aspirin IMpurity D)
• CAS NO: 530-75-6
• Molecular Formula: C₁₆H₁₂O₆
• Molecular Weight: 300.26
• EINECS: 208-493-6
• Product Categories: Chemical Impurities;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 530-75-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 153-160 °C
• Boiling Point: 361.5°C (rough estimate)
• Flash Point: 203.9 °C
• Appearance: White to almost white fine crystalline powder
• Density: 1.346
• Vapor Pressure: 1.7E-12mmHg at 25°C
• Refractive Index: 1.4600 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Sparingly), DMSO (Sparingly), Methanol (Slightly)
• PKA: 2.94±0.36(Predicted)
• Water Solubility: 20mg/L(21 oC)
• CAS DataBase Reference: ACETYLSALICYLSALICYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: ACETYLSALICYLSALICYLIC ACID(530-75-6)
• EPA Substance Registry System: ACETYLSALICYLSALICYLIC ACID(530-75-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25
• Hazardous Substances Data: 530-75-6(Hazardous Substances Data)

Usage

Chemical Properties

white to almost white fine crystalline powder

Uses

Different sources of media describe the Uses of 530-75-6 differently. You can refer to the following data:
1. analgesic, antipyretic
2. Acetylsalicylic Acid Impurity C

Purification Methods

Crystallise the analgesic from dilute AcOH or EtOH (m 161-162o), MeOH (m 165-168o), and *C6H6/EtOH (m 163-165o). Its solubilities in boiling Et2O, *C6H6 and EtOH are 1.4%, 2.2% and 33%, respectively. [Baker et al. J Chem Soc 201 1951, Garrett et al. J Am Pharm Soc 48 684 1959, Beilstein 10 I 41, 10 II 54, 10 IV 165.]

InChI:InChI=1/C16H12O6/c1-10(17)21-14-9-5-3-7-12(14)16(20)22-13-8-4-2-6-11(13)15(18)19/h2-9H,1H3,(H,18,19)/p-1

Upstream product

• 110-86-1 pyridine 
• 50-78-2 aspirin 
• 1466-82-6 aspirin anhydride 
• 54-21-7 sodium salicylate 
• 69-72-7 salicylic acid 
• 36335-42-9 (2-acetoxy-benzoyl)-carbonic acid ethyl ester 
• 5538-51-2 O-acetylsalicyloyl chloride 
• 67-64-1 acetone 
• 121-69-7 N,N-dimethyl-aniline 
• 552-94-3 2-hydroxy-benzoic acid, 2-carboxyphenyl ester 
• 108-24-7 acetic anhydride 
• 64-17-5 ethanol 

Downstream Products

• 85531-21-1 2-(2-acetoxy-benzoyloxy)-benzoic acid methyl ester 
• 6034-63-5 2-(2-acetoxy-benzoyloxy)-benzoic acid amide 
• 552-94-3 2-hydroxy-benzoic acid, 2-carboxyphenyl ester 
• 50-78-2 aspirin 
• 124118-53-2 2-(2-acetoxy-benzoyloxy)-benzoic acid-anhydride 
• 1003572-58-4 2-(chlorocarbonyl)phenyl 2-(acetyloxy)benzoate 
• 98281-97-1 [2-(2-acetoxy-benzoyloxy)-benzoic acid ]-acetic acid-anhydride 

Relevant articles and documents

COMPOSITIONS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES

The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.

Hydrolysis of acetylsalicylsalicylic acid and salicylsalicylic acid in aqueous solution

-

Solid-state stability of aspirin in the presence of excipients: Kinetic interpretation, modeling, and prediction

Salicylsalicylic acid and acetylsalicylsalicylic acid were identified as decomposition products of aspirin when mixtures of the drug, with magnesium stearate, were stored in the solid state at 60° and 75% relative humidity. The effect of increasing the concentration of magnesium stearate and the addition of other alkali stearates on the rate of decomposition of aspirin were studied. The validity of the theory that pH changes induced by the alkali stearates account for the catalytic effect of the lubricants on the decomposition was tested. The changes observed were modeled and the mechanism involved elucidated. The potential use of the melting points of aspirin mixtures in predicting the stability of the drug in such drug-excipient mixtures is demonstrated.